T. Rowe Price Associates’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21M | Buy |
632,734
+26,789
| +4% | +$798K | ﹤0.01% | 1024 |
|
|
2025
Q4 | $18.1M | Sell |
605,945
-352,526
| -37% | -$11.5M | ﹤0.01% | 1078 |
|
|
2025
Q3 | $34.6M | Sell |
958,471
-589,073
| -38% | -$19.4M | ﹤0.01% | 903 |
|
|
2025
Q2 | $55.7M | Buy |
1,547,544
+1,157,016
| +296% | +$43.1M | 0.01% | 701 |
|
|
2025
Q1 | $15.4M | Buy |
390,528
+93,427
| +31% | +$3.14M | ﹤0.01% | 1013 |
|
|
2024
Q4 | $8.94M | Buy |
297,101
+215,601
| +265% | +$6.19M | ﹤0.01% | 1173 |
|
|
2024
Q3 | $1.91M | Sell |
81,500
-6,421
| -7% | -$140K | ﹤0.01% | 1664 |
|
|
2024
Q2 | $1.56M | Buy |
87,921
+2,318
| +3% | +$37K | ﹤0.01% | 1686 |
|
|
2024
Q1 | $1.3M | Buy |
85,603
+5,015
| +6% | +$79.9K | ﹤0.01% | 1780 |
|
|
2023
Q4 | $1.38M | Buy |
80,588
+27,249
| +51% | +$317K | ﹤0.01% | 1716 |
|
|
2023
Q3 | $446K | Sell |
53,339
-244,700
| -82% | -$3.41M | ﹤0.01% | 2162 |
|
|
2023
Q2 | $7.4M | Buy |
298,039
+223,545
| +300% | +$5.77M | ﹤0.01% | 1123 |
|
|
2023
Q1 | $1.12M | Sell |
74,494
-18,172
| -20% | -$276K | ﹤0.01% | 1731 |
|
|
2022
Q4 | $1.1M | Sell |
92,666
-11,917
| -11% | -$86.5K | ﹤0.01% | 1729 |
|
|
2022
Q3 | $620K | Buy |
104,583
+4,326
| +4% | +$28.4K | ﹤0.01% | 2015 |
|
|
2022
Q2 | $426K | Sell |
100,257
-480,718
| -83% | -$3M | ﹤0.01% | 2284 |
|
|
2022
Q1 | $5.53M | Sell |
580,975
-17
| -0% | -$197 | ﹤0.01% | 1452 |
|
|
2021
Q4 | $11M | Sell |
580,992
-844,156
| -59% | -$21.9M | ﹤0.01% | 1395 |
|
|
2021
Q3 | $47.4M | Sell |
1,425,148
-458,503
| -24% | -$14.2M | ﹤0.01% | 1031 |
|
|
2021
Q2 | $73.1M | Buy |
1,883,651
+266,310
| +16% | +$10.5M | 0.01% | 896 |
|
|
2021
Q1 | $78M | Buy |
1,617,341
+216,496
| +15% | +$10.4M | 0.01% | 850 |
|
|
2020
Q4 | $72.9M | Buy |
1,400,845
+1,349,836
| +2,646% | +$45.6M | 0.01% | 832 |
|
|
2020
Q3 | $1.36M | Buy |
+51,009
| New | +$1.17M | ﹤0.01% | 1673 |
|
|
2018
Q4 | – | Sell |
-39,297
| Closed | -$220K | – | 2593 |
|
|
2018
Q3 | $220K | Buy |
39,297
+349
| +0.9% | +$3.99K | ﹤0.01% | 2442 |
|
|
2018
Q2 | $512K | Sell |
38,948
-788
| -2% | -$10.8K | ﹤0.01% | 2133 |
|
|
2018
Q1 | $564K | Sell |
39,736
-13,000
| -25% | -$166K | ﹤0.01% | 2043 |
|
|
2017
Q4 | $432K | Buy |
52,736
+38,000
| +258% | +$332K | ﹤0.01% | 2145 |
|
|
2017
Q3 | $175K | Hold |
14,736
| – | – | ﹤0.01% | 2439 |
|
|
2017
Q2 | $148K | Buy |
14,736
+36
| +0.2% | +$403 | ﹤0.01% | 2434 |
|
|
2017
Q1 | $171K | Hold |
14,700
| – | – | ﹤0.01% | 2425 |
|
|
2016
Q4 | $68K | Hold |
14,700
| – | – | ﹤0.01% | 2501 |
|
|
2016
Q3 | $114K | Buy |
+14,700
| New | +$94.5K | ﹤0.01% | 2430 |
|
Other funds holding TGTX
VPM
VCM
SCM
CAM
T. Rowe Price Associates's TGTX Position: Q1 2026 in Review
T. Rowe Price Associates increased its TG Therapeutics (TGTX) stake by 4.4% in Q1 2026, buying an estimated $798K and bringing the position to 632,734 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #1024.
T. Rowe Price Associates first reported a position in TGTX in Q3 2016 and has held it in 32 quarters since. The position peaked at $78M in Q1 2021. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.
- T. Rowe Price Associates held 632,734 shares of TG Therapeutics worth $21M as of Q1 2026.
- T. Rowe Price Associates bought 26,789 TG Therapeutics shares in Q1 2026, an estimated $798K.
- TG Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1024 holding.
- T. Rowe Price Associates first reported a position in TG Therapeutics in Q3 2016 and has held it in 32 quarters since.
- T. Rowe Price Associates's TG Therapeutics position peaked at $78M in Q1 2021.
- 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.